Last $2.82 USD
Change Today 0.00 / 0.00%
Volume 0.0
CPXX On Other Exchanges
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

celator pharmaceuticals inc (CPXX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/26/13 - $6.00
52 Week Low
04/8/14 - $2.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

celator pharmaceuticals inc (CPXX) Related Businessweek News

No Related Businessweek News Found

celator pharmaceuticals inc (CPXX) Details

Celator Pharmaceuticals, Inc., a pharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, represents a novel approach that identifies molar ratios of drugs that would deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle, which maintains the ratio in patients with improving clinical outcomes. The company’s pipeline includes two clinical stage products, CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase II studies for the treatment of acute myeloid leukemia (AML) and a Phase III study in patients with secondary AML; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidates comprise CPX-571, a liposomal formulation of irinotecan:cisplatin; and CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for in vitro and in vivo study. The company was founded in 1999 and is headquartered in Ewing, New Jersey.

21 Employees
Last Reported Date: 03/24/14
Founded in 1999

celator pharmaceuticals inc (CPXX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $527.1K
Founder, President and Chief Scientific Offic...
Total Annual Compensation: $367.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $377.3K
Compensation as of Fiscal Year 2013.

celator pharmaceuticals inc (CPXX) Key Developments

Celator Pharmaceuticals, Inc. Announces Board Changes

Celator Pharmaceuticals, Inc. announced the appointment of Michael R. Dougherty as Chairman of the Celator Board of Directors. Mr. Dougherty has served as a member of the Board since July 2013. He succeeds Joseph Mollica, who will continue to serve on the Board as an independent director. Mr. Dougherty most recently served as Chief Executive Officer of Kalidex Pharmaceuticals, Inc. Previously, Mr. Dougherty served as President and Chief Executive Officer of Adolor Corporation, and held senior leadership positions at several life science companies including Genomics Collaborative, Genaera Corporation and Centocor, Inc.

Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic and Pharmacodynamics Clinical Study of CPX-351

Celator Pharmaceuticals, Inc. announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of CPX-351 (cytarabine:daunorubicin) Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients. The open-label, single-arm, Phase 2 study is a thorough PK/PD assessment designed to: (1) measure the effects of CPX-351 on cardiac repolarization following the first induction cycle of CPX-351, (2) assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics, and (3) assess the impact of moderate renal impairment on cytarabine and daunorubicin pharmacokinetics. The study is expected to enroll 36 patients. Each patient will receive a first induction of CPX-351 on days 1, 3 and 5 and, if necessary, a second induction for patients with reduced leukemia/MDS burden not yet achieving a leukemia/MDS-free state. Responding patients are eligible for up to four consolidation courses. Analysis of treatment impact on cardiac electrophysiology, as measured by the QTc interval, and PK assessments will be performed only following the first induction course.

Celator Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Celator Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $4,791,194 or $0.18 per basic and diluted share on operating loss of $4,577,822 against net loss of $4,040,977 or $0.18 per basic and diluted on operating loss of $3,195,897 for the same period a year ago. For the six months, the company reported net loss of $9,068,695 or $0.35 per basic and diluted share on operating loss of $8,845,930 against net loss attributable to common stockholders of $13,724,925 or $0.77 per basic and diluted share on operating loss of $6,103,774 for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPXX:US $2.82 USD 0.00

CPXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPXX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CPXX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELATOR PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at